Posted by Incepta Pharmaceuticals Ltd.
Clinical Diabetes and Endocrinology Journal: Published: May 2022Diabetes Mellitus (DM) is a debilitating metabolic disorder
characterized by impaired insulin function, leading to chronic hyperglycemia.Diabetic nephropathy (DN) is one of the most common and
severe microvascular complications of DM, occurring in about 20–30% of diabetic
patients,...
Diabetes, Obesity and Metabolism Journal:
PubMedTAKE HOME MESSAGE:The study aims to investigate the
effect of sequential treatment escalation with empagliflozin and linagliptin on
laboratory markers of α- and β-cell function in people with type 2 diabetes
mellitus (T2DM) insufficiently controlled on metformin monotherapy.The researchers found t...
AHA Journals: Hypertension: Published on May, 2022Diabetes is a strong risk factor
for end-stage renal disease (ESRD). Hypertension also plays a crucial role
in the development and progression of kidney failure. Blood pressure (BP)
rises with declining kidney function which in turn aggravates hypertension. Moreover, as chronic kidney disease
(C...
Stepwise Approach of
Dengue Case ManagementPatients Group A: These are patients who are dengue
patients without warning sign and they may be sent home. These patients are
able to tolerate adequate volumes of oral fluids, pass urine at least once
every six hours. Patients Group B: These include patients with warning
signs. These are patients wh...
FDA News Release: Published on November, 2022Type one diabetes mellitus (T1DM)
is an autoimmune disease characterized by gradual destruction of beta cells in
islets of Langerhans. Teplizumab is a humanized anti- CD3 monoclonal antibody,
which have beneficial effects for T1DM patients.The U.S. Food and Drug
Administration (FDA) has approved tepl...
Coronavirus disease 2019 (COVID-19)
is one of the most significant pandemics in human history caused by the virus
known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
SARS-CoV-2 has infected >530 million people, of which >6.3 million have
died since June 23, 2022. Recent research has indicated that
COVID-19 might be a risk fa...
Nature Medicine: Published on November, 2022Obesity is a chronic, relapsing
disease with a substantial morbidity, mortality, and healthcare burden. Drug
interventions for the treatment of obesity provide a potential valuable adjunct
to lifestyle interventions, which often achieve only limited weight loss that
is difficult to maintain. Semagluti...
Journal of the American College of Cardiology: Published on December,
2022Healthy dietary patterns are rich
in micronutrients, but their influence on cardiovascular disease (CVD) risks
has not been systematically quantified.The goal of this study was to
provide a comprehensive and most up-to-date evidence-based map that
systematically quantifi...
Diabetes Care: Published on December 2022With the numbers of people with
type 2 diabetes rising worldwide, dietary modifications provide an essential
therapeutic approach for blood glucose, weight, and cardiovascular risk-factor
management. Intermittent fasting (IF) has
emerged as an alternative to classic daily caloric reduction. The approache...
ACP Journals: Annals of Internal Medicine: Published
on February 2023In this systematic review and
meta-analysis, the authors assessed whether vitamin D administration decreases
the risk for diabetes in individuals with prediabetes. TAKE-HOME MESSAGECombining data from three
randomized trials, the authors demonstrated that vitamin D reduced the...
AHA Journal: Circulation: Published on February,
2023Low-density lipoprotein cholesterol
(LDL-C) level is a well-established risk factor for atherosclerotic
cardiovascular disease. However, the optimal achieved LDL-C level with regard
to efficacy and safety in the long term remains unknown.TAKE-HOME MESSAGEThis study assessed the
relationship...
ADA Diabetes Care Journal:
Metformin
is the recommended first-line pharmacotherapy for patients with type 2 diabetes,
but most patients will ultimately require additional therapies to maintain
glycemic control.
Maintaining
intensive glucose control early in the disease process may lead to legacy
benefits that persist beyond the per...
